OncoMatch/Clinical Trials/NCT03778814
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Is NCT03778814 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TCR-T cells for nonsmall cell lung cancer.
Treatment: TCR-T cells — Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Prior therapy
Cannot have received: gene therapy
Lab requirements
Kidney function
adequate kidney function
Liver function
Child-Pugh-Turcotte score <7; adequate liver function
Cardiac function
adequate heart function
Child-Pugh-Turcotte score <7; Adequate heart,lung,liver,kidney function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify